Orig3n, Inc., a Boston, MA-based biomedical research company, received an addtional investment from Spectrum Health Ventures (SHV).
This round of funding was led by Hatteras Venture Partners with participation from all current syndicate members participated. Spectrum Health Ventures joined existing investors Hatteras, LabCorp, Syno Capital, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners, and 180 Degree Capital.
The company, which has raised over $30m in capital to date, also announced the addition of Byron Smith – currently a Principal at Mountain Group Partners (MGP), a fund dedicated to investing in and guiding transformation businesses in the life science and technology sectors – to its Board of Directors.
Orig3n will use the funds to expand and intensify its research efforts into the development of cell therapies.
Founded in 2014 and led by Robin Y. Smith, CEO, Orig3n provides DNA tests which leverage cellular science to develop personalized therapies for repairing tissue damage and disease.